Gilead Sciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Gilead Sciences (GILD).

Price Target Range — 9 Quarters

Analyst Consensus — 22 Analysts

18Buy

4Hold

Consensus RatingBuy# Analysts22Avg. Consensus PT$151Upside to Avg. PT-9.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 30, 2026	UBS	Michael Yee	PT Raise	Buy	$175→$195
Oct 30, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$170→$190
Oct 30, 2026	Citigroup	Geoff Meacham	PT Raise	Buy	$165→$188
Oct 30, 2026	Scotiabank	Louis Chen	PT Raise	Sector Outperform	$177→$200
Oct 30, 2026	TD Cowen	Tyler Van Buren	PT Raise	Buy	$160→$175
Oct 30, 2026	Morgan Stanley	Matthew Harrison	PT Raise	Overweight	$163→$183
Oct 30, 2026	Wells Fargo	Mohit Bansal	PT Raise	Overweight	$165→$190
Oct 30, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$158→$181
Oct 30, 2026	RBC Capital	Brian Abrahams	PT Raise	Sector Perform	$126→$131
Oct 30, 2026	Cantor Fitzgerald	Carter Gould	PT Raise	Overweight	$155→$175
Oct 30, 2026	Needham	Joseph Stringer	PT Raise	Buy	$170→$200
Oct 20, 2026	B of A Securities	Tim Anderson	PT Raise	Buy	$168→$172
Oct 8, 2026	RBC Capital	Brian Abrahams	PT Raise	Sector Perform	$123→$126
Oct 8, 2026	Cantor Fitzgerald	Carter Gould	Maintained	Overweight	$155
Oct 7, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$150→$158
Oct 7, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$160→$170
Oct 7, 2026	Morgan Stanley	Matthew Harrison	PT Cut	Overweight	$165→$163
Sep 10, 2026	HSBC	Morten Herholdt	PT Raise	Buy	$155→$175
Aug 5, 2026	RBC Capital	Brian Abrahams	PT Raise	Sector Perform	$120→$123
Aug 5, 2026	Cantor Fitzgerald	Carter Gould	Maintained	Overweight	$155

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $190

JP Morgan analyst Chris Schott maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $170 to $190.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Gilead Sciences, Raises Price Target to $175

TD Cowen analyst Tyler Van Buren maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $160 to $175.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Gilead Sciences, Raises Price Target to $183

Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $163 to $183.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Gilead Sciences, Raises Price Target to $190

Wells Fargo analyst Mohit Bansal maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $165 to $190.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $181

Truist Securities analyst Gregory Renza maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $158 to $181.

Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $131

RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform and raises the price target from $126 to $131.

Benzinga Newsdesk

Gilead Sciences Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Gilead Sciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $190

PRO
TD Cowen Maintains Buy on Gilead Sciences, Raises Price Target to $175

PRO
Morgan Stanley Maintains Overweight on Gilead Sciences, Raises Price Target to $183

PRO
Wells Fargo Maintains Overweight on Gilead Sciences, Raises Price Target to $190

PRO
Truist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $181

PRO
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $131

People Also Watch

People Also Watch

Gilead Sciences Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Gilead Sciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROJP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $190

PROTD Cowen Maintains Buy on Gilead Sciences, Raises Price Target to $175

PROMorgan Stanley Maintains Overweight on Gilead Sciences, Raises Price Target to $183

PROWells Fargo Maintains Overweight on Gilead Sciences, Raises Price Target to $190

PROTruist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $181

PRORBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $131

People Also Watch

People Also Watch

PRO
JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $190

PRO
TD Cowen Maintains Buy on Gilead Sciences, Raises Price Target to $175

PRO
Morgan Stanley Maintains Overweight on Gilead Sciences, Raises Price Target to $183

PRO
Wells Fargo Maintains Overweight on Gilead Sciences, Raises Price Target to $190

PRO
Truist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $181

PRO
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $131